Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
Is It Too Late To Reassess Teva (TEVA) After A 55% One Year Rally? [Yahoo! Finance]
Public advisory -Teva Octreotide for injectable suspension recalled due to potential drug quality issues [Yahoo! Finance]
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation [Yahoo! Finance]
Show more
Live Event:
Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team:
support@newsquantified.com